CGEN
Price
$1.66
Change
-$0.03 (-1.78%)
Updated
Jun 27 closing price
Capitalization
156.55M
32 days until earnings call
CYCN
Price
$3.00
Change
+$0.19 (+6.76%)
Updated
Jun 27 closing price
Capitalization
9.18M
Interact to see
Advertisement

CGEN vs CYCN

Header iconCGEN vs CYCN Comparison
Open Charts CGEN vs CYCNBanner chart's image
Compugen
Price$1.66
Change-$0.03 (-1.78%)
Volume$111.5K
Capitalization156.55M
Cyclerion Therapeutics
Price$3.00
Change+$0.19 (+6.76%)
Volume$95.46K
Capitalization9.18M
CGEN vs CYCN Comparison Chart in %
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. CYCN commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Buy and CYCN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CGEN: $1.66 vs. CYCN: $3.00)
Brand notoriety: CGEN and CYCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 52% vs. CYCN: 489%
Market capitalization -- CGEN: $155M vs. CYCN: $9.18M
CGEN [@Biotechnology] is valued at $155M. CYCN’s [@Biotechnology] market capitalization is $9.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileCYCN’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • CYCN’s FA Score: 1 green, 4 red.
According to our system of comparison, both CGEN and CYCN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 5 TA indicator(s) are bullish while CYCN’s TA Score has 4 bullish TA indicator(s).

  • CGEN’s TA Score: 5 bullish, 4 bearish.
  • CYCN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than CYCN.

Price Growth

CGEN (@Biotechnology) experienced а +1.22% price change this week, while CYCN (@Biotechnology) price change was +1.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CGEN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($157M) has a higher market cap than CYCN($9.18M). CGEN YTD gains are higher at: 8.497 vs. CYCN (-6.835). CYCN has higher annual earnings (EBITDA): -3.47M vs. CGEN (-14.79M). CGEN has more cash in the bank: 104M vs. CYCN (3.64M). CYCN has less debt than CGEN: CYCN (0) vs CGEN (2.77M). CGEN has higher revenues than CYCN: CGEN (27.6M) vs CYCN (2.08M).
CGENCYCNCGEN / CYCN
Capitalization157M9.18M1,710%
EBITDA-14.79M-3.47M427%
Gain YTD8.497-6.835-124%
P/E Ratio60.33N/A-
Revenue27.6M2.08M1,326%
Total Cash104M3.64M2,858%
Total Debt2.77M0-
FUNDAMENTALS RATINGS
CGEN vs CYCN: Fundamental Ratings
CGEN
CYCN
OUTLOOK RATING
1..100
8988
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
4745
P/E GROWTH RATING
1..100
28100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCN's Valuation (20) in the null industry is somewhat better than the same rating for CGEN (77) in the Biotechnology industry. This means that CYCN’s stock grew somewhat faster than CGEN’s over the last 12 months.

CYCN's Profit vs Risk Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that CYCN’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (95) in the Biotechnology industry is in the same range as CYCN (96) in the null industry. This means that CGEN’s stock grew similarly to CYCN’s over the last 12 months.

CYCN's Price Growth Rating (45) in the null industry is in the same range as CGEN (47) in the Biotechnology industry. This means that CYCN’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (28) in the Biotechnology industry is significantly better than the same rating for CYCN (100) in the null industry. This means that CGEN’s stock grew significantly faster than CYCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENCYCN
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
THNPF41.262.79
+7.25%
Technip Energies NV
KYOCY11.950.08
+0.65%
Kyocera Corp.
ELLH16.00N/A
N/A
Elah Holdings Inc.
QQQFF0.02N/A
N/A
Quizam Media Corporation
CAOEF16.17N/A
N/A
Canon Electronics, Inc.

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with BDTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-1.78%
BDTX - CGEN
46%
Loosely correlated
-4.07%
ROIV - CGEN
42%
Loosely correlated
-1.81%
ARWR - CGEN
40%
Loosely correlated
+0.06%
BBIO - CGEN
40%
Loosely correlated
-0.59%
RLAY - CGEN
39%
Loosely correlated
-0.60%
More

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with BLUE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then BLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
+6.86%
BLUE - CYCN
36%
Loosely correlated
N/A
HRTX - CYCN
35%
Loosely correlated
-0.93%
GDTC - CYCN
30%
Poorly correlated
+1.30%
ENTO - CYCN
25%
Poorly correlated
-12.87%
CGEN - CYCN
23%
Poorly correlated
-1.78%
More